Arno Therapeutics 10-Q 14 Aug 14 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Jun. 30, 2014	Aug. 14, 2014
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Entity Registrant Name	'Arno Therapeutics, Inc	'
Entity Central Index Key	'0001195116	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'ARNI	'
Entity Common Stock, Shares Outstanding	'	20,370,331

CONDENSED_BALANCE_SHEETS

CONDENSED BALANCE SHEETS (USD $)	Jun. 30, 2014	Dec. 31, 2013
Current assets	'	'
Cash and cash equivalents	$15,844,600	$26,774,203
Other receivables	8,837	0
Prepaid expenses and other current assets	58,633	86,266
Total current assets	15,912,070	26,860,469
Property and equipment, net	25,256	11,720
Security deposit	10,455	10,455
Total assets	15,947,781	26,882,644
Current liabilities	'	'
Accounts payable	1,361,737	2,941,998
Accrued expenses and other current liabilities	1,117,325	925,255
Due to related party	0	26,039
Deferred rent	4,423	7,797
Total current liabilities	2,483,485	3,901,089
Derivative liabilities	20,881,401	35,864,881
Total liabilities	23,364,886	39,765,970
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' DEFICIT	'	'
Preferred stock, $0.0001 par value, 35,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.0001 par value, 500,000,000 shares authorized, 20,370,331 shares issued and outstanding	5,465	5,465
Additional paid-in capital	79,086,995	76,668,966
Deficit accumulated during the development stage	-86,509,565	-89,557,757
Total stockholders' deficit	-7,417,105	-12,883,326
Total liabilities and stockholders' deficit	$15,947,781	$26,882,644

CONDENSED_BALANCE_SHEETS_Paren

CONDENSED BALANCE SHEETS (Parenthetical) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	35,000,000	35,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	20,370,331	20,370,331
Common stock, shares outstanding	20,370,331	20,370,331

CONDENSED_STATEMENTS_OF_OPERAT

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended		107 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Operating expenses:	'	'	'	'	'
Research and development	$4,083,398	$2,741,756	$8,518,114	$5,734,787	$58,839,691
General and administrative	1,680,105	668,011	3,409,157	1,519,848	16,215,949
Total operating expenses	5,763,503	3,409,767	11,927,271	7,254,635	75,055,640
Loss from operations	-5,763,503	-3,409,767	-11,927,271	-7,254,635	-75,055,640
Other (expense) income:	'	'	'	'	'
Interest income	13,344	2,932	24,860	6,992	456,717
Interest expense	0	-1,858,887	0	-4,017,608	-26,190,285
Other (expense) income	9,244,792	-6,039,108	14,950,603	-973,467	14,279,643
Total other (expense) income	9,258,136	-7,895,063	14,975,463	-4,984,083	-11,453,925
Net income/(loss)	$3,494,633	($11,304,830)	$3,048,192	($12,238,718)	($86,509,565)
Net income/(loss) per share - basic	$0.17	($2.35)	$0.15	($2.61)	'
Weighted-average shares outstanding- basic	20,370,331	4,814,822	20,370,331	4,684,384	'
Net income/(loss) per share - diluted	$0.14	($2.35)	$0.12	($2.61)	'
Weighted-average shares outstanding- diluted	24,802,522	4,814,822	24,804,963	4,684,384	'

CONDENSED_STATEMENT_OF_STOCKHO

CONDENSED STATEMENT OF STOCKHOLDERS' (DEFICIT) EQUITY (USD $)

Total

Convertible Debt

2008 services

Founders

Private Placement

Notes Payable

PREFERRED

PREFERRED STOCK

PREFERRED STOCK

PREFERRED STOCK

PREFERRED STOCK

PREFERRED STOCK

PREFERRED STOCK

PREFERRED STOCK

COMMON STOCK

COMMON STOCK

COMMON STOCK

COMMON STOCK

COMMON STOCK

COMMON STOCK

COMMON STOCK

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Additional paid-in capital

Deficit accumulated during the development stage

Deficit accumulated during the development stage

Deficit accumulated during the development stage

Deficit accumulated during the development stage

Deficit accumulated during the development stage

Deficit accumulated during the development stage

Deficit accumulated during the development stage

Convertible Debt

2008 services

Founders

Private Placement

Notes Payable

PREFERRED

Convertible Debt

2008 services

Founders

Private Placement

Notes Payable

PREFERRED

Convertible Debt

2008 services

Founders

Private Placement

Notes Payable

PREFERRED

Convertible Debt

2008 services

Founders

Private Placement

Notes Payable

PREFERRED

Beginning Balance at Jul. 31, 2005

$0

'

'

'

'

'

'

$0

'

'

'

'

'

'

$0

'

'

'

'

'

'

$0

'

'

'

'

'

'

$0

'

'

'

'

'

'

Beginning Balance (in shares) at Jul. 31, 2005

'

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares (in share)

'

'

'

'

'

'

'

'

'

'

0

0

'

'

'

'

'

1,246,100

920,086

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares

'

'

'

5,000

17,690,037

'

'

'

'

'

0

0

'

'

'

'

'

997

736

'

'

'

'

'

4,003

17,689,301

'

'

'

'

'

0

0

'

'

Stock based compensation for services

2,125,952

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

2,125,952

'

'

'

'

'

'

0

'

'

'

'

'

'

Convertible preferred units issued in 2010 private placement, net of issuance costs of $1,299,770 (in share)

'

'

'

'

'

'

'

'

'

'

'

1,909,250

'

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible preferred units issued in 2010 private placement, net of issuance costs of $1,299,770

'

'

'

'

13,509,510

'

'

'

'

'

'

1,527

'

'

'

'

'

'

0

'

'

'

'

'

'

13,507,983

'

'

'

'

'

'

0

'

'

Issuance of Units

'

'

480,400

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

480,400

'

'

'

'

'

'

0

'

'

'

'

Note discount arising from 2008 note conversion

475,391

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

475,391

'

'

'

'

'

'

0

'

'

'

'

'

'

Warrants issued in connection with convertible preferred units issued in 2010 private placement

-3,340,421

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

-3,340,421

'

'

'

'

'

'

0

'

'

'

'

'

'

Warrants issued in connection with 2008 note conversion

348,000

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

348,000

'

'

'

'

'

'

0

'

'

'

'

'

'

Reverse merger transaction in 2008- elimination of accumulated deficit

-120,648

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

-120,648

'

'

'

'

'

'

0

'

'

'

'

'

'

Reverse merger transaction in 2008 -previously issued Laurier common stock (in shares)

'

'

'

'

'

'

'

0

'

'

'

'

'

'

137,525

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Reverse merger transaction in 2008 -previously issued Laurier common stock

120,648

'

'

'

'

'

'

0

'

'

'

'

'

'

110

'

'

'

'

'

'

120,538

'

'

'

'

'

'

0

'

'

'

'

'

'

Warrants issues to placement agents in connection with 2010 private placement

464,720

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

464,720

'

'

'

'

'

'

0

'

'

'

'

'

'

Preferred stock conversion (shares)

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

'

'

'

245,292

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock conversion

'

'

'

'

'

4,278,518

'

'

'

'

'

'

0

'

'

'

'

'

'

196

'

'

'

'

'

'

4,278,322

'

'

'

'

'

'

0

'

Stock option exercise (in shares)

'

'

'

'

'

'

'

0

'

'

'

'

'

'

2,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock option exercise

2,600

'

'

'

'

'

'

0

'

'

'

'

'

'

2

'

'

'

'

'

'

2,598

'

'

'

'

'

'

0

'

'

'

'

'

'

Net income/(loss)

-27,603,887

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

-27,603,887

'

'

'

'

'

'

Ending Balance at Dec. 31, 2010

8,435,820

'

'

'

'

'

'

1,527

'

'

'

'

'

'

2,041

'

'

'

'

'

'

36,036,139

'

'

'

'

'

'

-27,603,887

'

'

'

'

'

'

Ending Balance (in shares) at Dec. 31, 2010

'

'

'

'

'

'

'

1,909,250

'

'

'

'

'

'

2,551,503

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation for services

707,284

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

707,284

'

'

'

'

'

'

0

'

'

'

'

'

'

Preferred stock conversion (shares)

'

'

'

'

'

'

'

'

'

'

'

'

'

-1,909,250

'

'

'

'

'

'

1,909,250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock conversion

'

'

'

'

'

'

0

'

'

'

'

'

'

-1,527

'

'

'

'

'

'

1,527

'

'

'

'

'

'

0

'

'

'

'

'

'

0

Issuance of stock dividend in connection with conversion of preferred stock (in shares)

'

'

'

'

'

'

'

0

'

'

'

'

'

'

39,884

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of stock dividend in connection with conversion of preferred stock

0

'

'

'

'

'

'

0

'

'

'

'

'

'

32

'

'

'

'

'

'

-32

'

'

'

'

'

'

0

'

'

'

'

'

'

Grant of restricted shares (in shares)

'

'

'

'

'

'

'

0

'

'

'

'

'

'

31,250

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Grant of restricted shares

115,168

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

115,168

'

'

'

'

'

'

0

'

'

'

'

'

'

Stock option exercise (in shares)

'

'

'

'

'

'

'

0

'

'

'

'

'

'

6,231

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock option exercise

6,480

'

'

'

'

'

'

0

'

'

'

'

'

'

5

'

'

'

'

'

'

6,475

'

'

'

'

'

'

0

'

'

'

'

'

'

Net income/(loss)

-7,909,113

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

-7,909,113

'

'

'

'

'

'

Ending Balance at Dec. 31, 2011

1,355,639

'

'

'

'

'

'

0

'

'

'

'

'

'

3,605

'

'

'

'

'

'

36,865,034

'

'

'

'

'

'

-35,513,000

'

'

'

'

'

'

Ending Balance (in shares) at Dec. 31, 2011

'

'

'

'

'

'

'

0

'

'

'

'

'

'

4,538,118

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation for services

722,811

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

722,811

'

'

'

'

'

'

0

'

'

'

'

'

'

Issuance of common shares pursuant to placement agent agreement (in shares)

'

'

'

'

'

'

'

0

'

'

'

'

'

'

7,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares pursuant to placement agent agreement

43,500

'

'

'

'

'

'

0

'

'

'

'

'

'

6

'

'

'

'

'

'

43,494

'

'

'

'

'

'

0

'

'

'

'

'

'

Net income/(loss)

-14,387,782

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

-14,387,782

'

'

'

'

'

'

Ending Balance at Dec. 31, 2012

-12,265,832

'

'

'

'

'

'

0

'

'

'

'

'

'

3,611

'

'

'

'

'

'

37,631,339

'

'

'

'

'

'

-49,900,782

'

'

'

'

'

'

Ending Balance (in shares) at Dec. 31, 2012

'

'

'

'

'

'

'

0

'

'

'

'

'

'

4,545,618

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares (in share)

'

'

'

'

'

'

'

'

0

'

'

0

'

'

'

7,030,753

'

'

8,413,354

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares

'

22,277,098

'

'

9,158,253

'

'

'

0

'

'

0

'

'

'

708

'

'

841

'

'

'

22,276,390

'

'

9,157,412

'

'

'

0

'

'

0

'

'

Stock based compensation for services

1,456,776

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

1,456,776

'

'

'

'

'

'

0

'

'

'

'

'

'

Issuance of Units

5,233,844

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

5,233,844

'

'

'

'

'

'

0

'

'

'

'

'

'

Issuance of common shares in lieu of liquidated damages (in shares)

'

'

'

'

'

'

'

0

'

'

'

'

'

'

380,606

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares in lieu of liquidated damages

913,510

'

'

'

'

'

'

0

'

'

'

'

'

'

305

'

'

'

'

'

'

913,205

'

'

'

'

'

'

0

'

'

'

'

'

'

Net income/(loss)

-39,656,975

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

-39,656,975

'

'

'

'

'

'

Ending Balance at Dec. 31, 2013

-12,883,326

'

'

'

'

'

'

0

'

'

'

'

'

'

5,465

'

'

'

'

'

'

76,668,966

'

'

'

'

'

'

-89,557,757

'

'

'

'

'

'

Ending Balance (in shares) at Dec. 31, 2013

'

'

'

'

'

'

'

0

'

'

'

'

'

'

20,370,331

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock based compensation for services

2,418,029

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

2,418,029

'

'

'

'

'

'

0

'

'

'

'

'

'

Net income/(loss)

3,048,192

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

0

'

'

'

'

'

'

3,048,192

'

'

'

'

'

'

Ending Balance at Jun. 30, 2014

($7,417,105)

'

'

'

'

'

'

$0

'

'

'

'

'

'

$5,465

'

'

'

'

'

'

$79,086,995

'

'

'

'

'

'

($86,509,565)

'

'

'

'

'

'

Ending Balance (in shares) at Jun. 30, 2014

'

'

'

'

'

'

'

0

'

'

'

'

'

'

20,370,331

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

CONDENSED_STATEMENT_OF_STOCKHO1

CONDENSED STATEMENT OF STOCKHOLDERS' (DEFICIT) EQUITY (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2010	Dec. 31, 2008	Dec. 31, 2013	Dec. 31, 2005
		COMMON STOCK	COMMON STOCK	Founders
			Private Placement	COMMON STOCK
Issuance of common shares to founder	'	'	'	$0.00
Stock issuance costs	$1,299,770	$141,646	$766,803	'

CONDENSED_STATEMENTS_OF_CASH_F

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended		107 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Cash flows from operating activities:	'	'	'
Net income/(loss)	$3,048,192	($12,238,718)	($86,509,565)
Adjustment to reconcile net income/(loss) to net cash used in operating activities:	'	'	'
Depreciation and amortization	6,561	6,679	134,658
Stock-based compensation	2,418,029	699,298	7,546,020
Change in fair value of derivative liability	-14,983,480	980,959	-13,258,725
Write-off of intangible assets	0	0	85,125
Warrants issued for services	0	0	480,400
Warrants issued in connection with note conversion	0	0	348,000
Note discount arising from beneficial conversion feature	0	0	475,391
Loss on disposal of assets	0	0	5,357
Noncash interest expense	0	4,497,357	25,564,067
Changes in operating assets and liabilities:	'	'	'
Other Receivables	-8,837	0	-8,837
Prepaid expenses and other current assets	27,633	35,220	-58,633
Security deposit	0	0	-10,455
Accounts payable	-1,580,261	627,612	1,361,737
Accrued expenses	192,070	-994,727	532,489
Deferred rent	-3,374	-2,333	4,423
Due to related party	-26,039	-394	0
Net cash used in operating activities	-10,909,506	-6,389,047	-63,308,548
Cash flows from investing activities:	'	'	'
Purchase of property and equipment	-20,097	0	-120,271
Cash paid for intangible assets	0	0	-85,125
Proceeds from related party advance	0	0	525,000
Repayment of related party advance	0	0	-525,000
Net cash used in investing activities	-20,097	0	-205,396
Cash flows from financing activities:	'	'	'
Proceeds from issuance of common stock to founders	0	0	5,000
Proceeds from issuance of preferred stock in private placement, net	0	0	13,974,230
Proceeds from issuance of units in private placement, net	0	0	37,115,377
Deferred financing fees paid	0	0	-1,217,345
Proceeds from issuance of notes payable	0	0	1,000,000
Repayment of notes payable	0	0	-1,000,000
Proceeds from issuance of convertible notes payable	0	0	3,967,000
Proceeds from issuance of convertible debentures payable	0	0	14,857,200
Proceeds from issuance of Class C warrants	0	0	10,648,002
Proceeds from exercise of stock options	0	0	9,080
Net cash provided by financing activities	0	0	79,358,544
Net increase (decrease) in cash and cash equivalents	-10,929,603	-6,389,047	15,844,600
Cash and cash equivalents at beginning of period	26,774,203	10,943,437	0
Cash and cash equivalents at end of period	15,844,600	4,554,390	15,844,600
Supplemental schedule of cash flows information:	'	'	'
Cash paid for interest	0	63,088	342,318
Supplemental schedule of non-cash investing and financing activities:	'	'	'
Conversion of debentures into common stock	0	13,116	14,293
Conversion of notes payable and interest to common stock	0	0	4,278,518
Common shares of Laurier issued in reverse merger transaction	0	0	110
Issuance of common shares in lieu of liquidated damages	0	913,510	913,510
Issuance of common shares in lieu of accrued and additional interest	0	0	2,016,804
Issuance of warrants in connection with private placement of convertible preferred units	0	0	3,340,421
Issuance of warrants in connection with private placement of convertible debentures	0	0	12,973,055
Issuance of common stock pursuant to placement agent agreement	0	0	43,500
Preferred stock dividends settled in common stock	$0	$0	$319,074

DESCRIPTION_OF_BUSINESS

DESCRIPTION OF BUSINESS	6 Months Ended
	Jun. 30, 2014
Business Combination, Description [Abstract]	'
DESCRIPTION OF BUSINESS	'
	1. DESCRIPTION OF BUSINESS
	Arno Therapeutics, Inc. (“Arno” or the “Company”) develops innovative drug candidates intended to treat patients with cancer. The Company was incorporated in Delaware in March 2000, at which time its name was Laurier International, Inc. (“Laurier”). Pursuant to an Agreement and Plan of Merger dated March 6, 2008 (as amended, the “Merger Agreement”), by and among the Company, Arno Therapeutics, Inc., a Delaware corporation formed on August 1, 2005 (“Old Arno”), and Laurier Acquisition, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Laurier Acquisition”), on June 3, 2008, Laurier Acquisition merged with and into Old Arno, with Old Arno remaining as the surviving corporation and a wholly-owned subsidiary of Laurier. Immediately following this merger, Old Arno merged with and into Laurier and Laurier’s name was changed to Arno Therapeutics, Inc. These two merger transactions are hereinafter collectively referred to as the “Merger.” Immediately following the Merger, the former stockholders of Old Arno collectively held 95% of the outstanding common stock of Laurier, assuming the issuance of all shares issuable upon the exercise of outstanding options and warrants, and all of the officers and directors of Old Arno in office immediately prior to the Merger were appointed as the officers and directors of Laurier immediately following the Merger. Further, Laurier was a non-operating shell company prior to the Merger. The merger of a private operating company into a non-operating public shell corporation with nominal net assets is considered to be a capital transaction in substance, rather than a business combination, for accounting purposes. Accordingly, the Company treated this transaction as a capital transaction without recording goodwill or adjusting any of its other assets or liabilities. All costs incurred in connection with the Merger have been expensed. Upon completion of the Merger, the Company adopted Old Arno’s business plan.

BASIS_OF_PRESENTATION_AND_SUMM

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	'
	2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	The Company is a development stage enterprise since it has not yet generated any revenue from the sale of products and, through June 30, 2014, its efforts have been principally devoted to developing its licensed technologies and raising capital. Accordingly, the accompanying condensed financial statements have been prepared in accordance with the provisions of Accounting Standards Codification (“ASC”) 915, “Development Stage Entities.” The Company has experienced net losses since its inception and has an accumulated deficit of approximately $86.5 million at June 30, 2014. The Company expects to incur substantial and increasing losses and to have negative net cash flows from operating activities as it expands its technology portfolio and engages in further research and development activities, particularly from conducting clinical trials, manufacturing activities and pre-clinical studies.
	The accompanying unaudited Condensed Financial Statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q adopted under the Securities Exchange Act of 1934, as amended. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of Arno’s management, the accompanying Condensed Financial Statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary to present fairly the financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. The interim results for the periods ended June 30, 2014 are not necessarily indicative of results for the full 2014 fiscal year or any other future interim periods. Because the Merger was accounted for as a reverse acquisition under generally accepted accounting principles, the financial statements for periods prior to September 3, 2008, reflect only the operations of Old Arno.
	Effective as of the close of business on October 29, 2013, the Company amended its Amended and Restated Certificate of Incorporation to effect a combination (“Reverse Stock Split”) of the Common Stock at a ratio of one-for-eight. All historical share and per share amounts have been adjusted to reflect the Reverse Stock Split.
	These unaudited Condensed Financial Statements have been prepared by management and should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission.
	The preparation of financial statements in conformity with generally accepted accounting principles requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates and assumptions principally relate to services performed by third parties but not yet invoiced, estimates of the fair value and forfeiture rates of stock options issued to employees and consultants, and estimates of the probability and potential magnitude of contingent liabilities. Actual results could differ from those estimates.
	Research and Development
	Research and development costs are charged to expense as incurred. Research and development includes employee costs, fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated office, insurance, depreciation, and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial and the invoices received from its external service providers. The Company adjusts its accruals when actual costs become known. Costs related to the acquisition of technology rights for which development work is still in process are charged to operations as incurred and considered a component of research and development expense.
	Warrant Liability
	The Company accounts for the warrants issued in connection with the 2013, 2012 and 2010 Purchase Agreements (see Note 7) in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classify the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. The fair value of warrants issued by the Company, in connection with private placements of securities, has been estimated using a Monte Carlo simulation model and, in doing so, the Company’s management utilized a third-party valuation report. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error.

LIQUIDITY_AND_CAPITAL_RESOURCE

LIQUIDITY AND CAPITAL RESOURCES	6 Months Ended
	Jun. 30, 2014
Working Capital Information [Abstract]	'
LIQUIDITY AND CAPITAL RESOURCES	'
	3. LIQUIDITY AND CAPITAL RESOURCES
	Cash resources as of June 30, 2014 were approximately $15.8 million, compared to approximately $26.8 million as of December 31, 2013. Based on its resources at June 30, 2014 and the current plan of expenditure on continuing development of the Company’s current product candidates, the Company believes that it has sufficient capital to fund its operations into the first quarter of 2015. However, the Company will need substantial additional financing in order to fund its operations beyond such period and thereafter until it can achieve profitability, if ever. The Company’s continued operations will depend on its ability to raise additional funds through various potential sources, such as equity and debt financing, or to license its product candidates to another pharmaceutical company. The Company will continue to fund operations from cash on hand and through sources of capital similar to those previously described. The Company cannot assure that it will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs.
	The success of the Company depends on its ability to develop new products to the point of regulatory approval and subsequent revenue generation and, accordingly, to raise enough capital to finance these developmental efforts. Management plans to raise additional capital either by selling shares of its stock or other securities, issuing debt or by licensing one or more of its products to finance the continued operating and capital requirements of the Company. Amounts raised will be used to further develop the Company’s product candidates, acquire rights to additional product candidates and for other working capital purposes. While the Company will extend its best efforts to raise additional capital to fund all operations beyond the first quarter of 2015, management can provide no assurances that the Company will be successful in raising sufficient funds.
	In addition, to the extent that the Company raises additional funds by issuing shares of its common stock or other securities convertible or exchangeable for shares of common stock, stockholders will experience dilution, which may be significant. In the event the Company raises additional capital through debt financings, the Company may incur significant interest expense and become subject to covenants in the related transaction documentation that may affect the manner in which the Company conducts its business. To the extent that the Company raises additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to its technologies or product candidates, or grant licenses on terms that may not be favorable to the Company. Any or all of the foregoing may have a material adverse effect on the Company’s business and financial performance.

BASIC_AND_DILUTED_INCOMELOSS_P

BASIC AND DILUTED INCOME/(LOSS) PER SHARE	6 Months Ended
	Jun. 30, 2014
Earnings Per Share, Basic and Diluted [Abstract]	'
BASIC AND DILUTED INCOME/(LOSS) PER SHARE	'
	4. BASIC AND DILUTED INCOME/(LOSS) PER SHARE
	Basic net income/(loss) per share is calculated based on the weighted-average number of shares of common stock outstanding during the period. Diluted net income per share is calculated based on the weighted-average number of shares of common stock and other dilutive securities outstanding during the period. The potential dilutive shares of common stock resulting from the assumed exercise of stock options and warrants are determined under the treasury stock method.
	The following table is a reconciliation of the numerator and denominator used in the calculation of basic and diluted net income/(loss) per share.
		Three months ended June 30,				Six months ended June 30,
		2014		2013		2014		2013
	Numerator:
	Net income/(loss)	$	3,494,633	$	-11,304,830	$	3,048,192	$	-12,238,718
	Denominator:
	Weighted-average shares of common stock outstanding used in the calculation of basic net income/(loss) per share		20,370,331		4,814,822		20,370,331		4,684,384
	Effect of dilutive securities:
	Warrants to purchase common stock		4,432,191		-		4,434,632		-
	Weighted-average shares of common stock outstanding used in the calculation of diluted net income/(loss) per share		24,802,522		4,814,822		24,804,963		4,684,384
	For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted net income/(loss) per share if their effect is anti-dilutive. The aggregate number of common equivalent shares (related to options, warrants and convertible debentures) that have been excluded from the computations of diluted net income/(loss) per common share at June 30, 2014 and 2013 were 51,464,983 and 7,291,312, respectively, as their exercise prices are greater than the fair market price per common share as of June 30, 2014 and 2013, respectively.

INTANGIBLE_ASSETS_AND_INTELLEC

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	6 Months Ended
	Jun. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	'
	5. INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY
	License Agreements
	Onapristone License Agreement
	The Company’s rights to onapristone are governed by a license agreement with Invivis Pharmaceuticals, Inc. (“Invivis”), dated February 13, 2012. Under this agreement, the Company holds an exclusive, royalty-bearing license for the rights to commercialize onapristone for all therapeutic uses. The license agreement provides the Company with worldwide rights to develop and commercialize onapristone with the exception of France; provided, however, that the Company has an option to acquire French commercial rights from Invivis upon notice to Invivis together with additional consideration.
	The onapristone license agreement provides the Company with exclusive, worldwide rights to a patent portfolio claiming priority to a United States provisional patent application that relates to assays for predictive biomarkers for anti-progestin efficacy. If the pending patent application issues, the issued patent would be scheduled to expire in 2031. The Company intends to expand its patent portfolio by filing additional patent applications covering the use of onapristone and/or a companion diagnostic product. The Company has filed patent applications directed to forms of the onapristone compound.
	The Company made a one-time cash payment of $500,000 to Invivis upon execution of the license agreement on February 13, 2012. Additionally, Invivis will receive performance-based cash payments of up to an aggregate of $15.1 million upon successful completion of clinical and regulatory milestones relating to onapristone, which milestones include the marketing approval of onapristone in multiple indications in the United States or the European Union as well as Japan. The first milestone was due upon the dosing of the first patient in a pharmacokinetic study and was achieved during August 2013 and the Company made a $150,000 payment to Invivis during October 2013. The Company made its next milestone payment of $100,000 to Invivis upon the dosing of the first subject in the first Company-sponsored Phase I clinical trial of onapristone in January 2014. In addition, the Company will pay Invivis low single digit sales royalties based on net sales of onapristone by the Company or any of its sublicensees. Pursuant to a separate services agreement which expired in April 2014, Invivis provided the Company with certain clinical development support services, which includes the assignment of up to two full-time employees to perform such services, in exchange for a monthly cash payment of approximately $70,833. Effective April 1, 2014, the Company renewed the services agreement for a period of one year for a monthly cash payment of $50,000.
	Under the license agreement with Invivis, the Company also agreed to indemnify and hold Invivis and its affiliates harmless from any and all claims arising out of or in connection with the production, manufacture, sale, use, lease, consumption or advertisement of onapristone, provided, however, that the Company shall have no obligation to indemnify Invivis for claims that (a) any patent rights infringe third party intellectual property, (b) arise out of the gross negligence or willful misconduct of Invivis, or (c) result from a breach of any representation, warranty confidentiality obligation of Invivis under the license agreement. The license agreement will terminate upon the later of (i) the last to expire valid claim contained in the patent rights, and (ii) February 13, 2032. In general, Invivis may terminate the license agreement at any time upon a material breach by the Company to the extent the Company fails to cure any such breach within 90 days after receiving notice of such breach or in the event the Company files for bankruptcy. The Company may terminate the agreement for any reason upon 90 days’ prior written notice.
	University of Minnesota License
	In February 2014, the Company entered into an Exclusive Patent License Agreement with the Regents of the University of Minnesota (the “University”), pursuant to which Arno was granted an exclusive, worldwide, royalty-bearing license for the rights to develop and commercialize technology embodied by certain patent applications relating to a gene expression signature derived from archived breast cancer tissue samples. The Company plans to develop and commercialize this technology as part of its companion diagnostic development program as a tool to identify progesterone-stimulated pathway activation, which in turn may identify patients who would be more likely to benefit from treatment with onapristone.
	The license agreement requires the Company to use commercially reasonable efforts to commercialize the licensed technology as soon as practicable, and includes several performance milestones relating to the development and commercialization of the technology to be achieved by specified dates beginning in the second quarter of 2014 and continuing during the term of the agreement. Under the terms of the agreement, Arno made a small one-time cash payment and reimbursed the University for past patent expenses it has incurred. The agreement also provides for royalties to be paid to the University on net sales of “Licensed Products” (as defined in the agreement) at a rate in the low-single digits, which royalty obligation terminates on a licensed product-by-licensed product and country-by-country basis upon the first date when there is no longer a valid claim under a licensed patent or patent application covering such licensed product in the country where the licensed product is made or sold.
	The term of the license agreement continues until the last date on which there is any active licensed patent or pending patent application. The University may terminate the agreement earlier upon certain Arno breaches that remain uncured for a period specified in the agreement. The University may also terminate the agreement if Arno voluntarily files for bankruptcy or similar proceeding, or if a petition for an involuntary bankruptcy proceeding is filed and is not released for 60 days. The agreement may be immediately terminated upon notice to Arno if the Company commences or maintains a proceeding in which it asserts that the licensed patents are invalid or unenforceable. Arno may terminate the agreement at any time and for any reason upon 90 days’ written notice.
	The license agreement further provides that the Company will indemnify and hold the University and its affiliates harmless from any and all suits, actions, claims, liabilities, demands, damages, losses or expenses relating to Arno’s exercise of its rights under the agreement, including the right to commercialize the licensed technology. The University is required to indemnify Arno with respect to claims relating to or resulting from its breach of the agreement.
	AR-12 and AR-42 License Agreements
	The Company’s rights to both AR-12 and AR-42 are governed by separate license agreements with The Ohio State University Research Foundation (“Ohio State”) entered into in January 2008. Pursuant to each of these agreements, Ohio State granted the Company exclusive, worldwide, royalty-bearing licenses to commercialize certain patent applications, know-how and improvements relating to AR-12 and AR-42 for all therapeutic uses.
	In 2008, pursuant to the Company’s license agreements for AR-12 and AR-42, the Company made one-time cash payments to Ohio State in the aggregate amount of $450,000 and reimbursed it for past patent expenses. Additionally, the Company is required to make performance-based cash payments upon successful completion of clinical and regulatory milestones relating to AR-12 and AR-42 in the United States, Europe and Japan. The license agreements for AR-12 and AR-42 provide for aggregate potential milestone payments of up to $6.1 million for AR-12, of which $5.0 million is due only after marketing approval in the United States, Europe and Japan, and $5.1 million for AR-42, of which $4.0 million is due only after marketing approval in the United States, Europe and Japan. In September 2009, the Company paid Ohio State a milestone payment upon the commencement of the first Company-sponsored Phase I clinical study of AR-12. The first milestone payment for AR-42 will be due when the first patient is dosed in the first Company-sponsored clinical trial, which is not expected to occur in 2014. Pursuant to the license agreements for AR-12 and AR-42, the Company must pay Ohio State royalties on net sales of licensed products at rates in the low-single digits. To the extent the Company enters into a sublicensing agreement relating to either or both of AR-12 or AR-42, the Company will be required to pay Ohio State a portion of all non-royalty income received from such sublicensee. The Company does not expect to be required to make any milestone payments under these license agreements during 2014.
	The license agreements with Ohio State further provide that the Company will indemnify Ohio State from any and all claims arising out of the death of or injury to any person or persons or out of any damage to property, or resulting from the production, manufacture, sale, use, lease, consumption or advertisement of either AR-12 or AR-42, except to the extent that any such claim arises out of the gross negligence or willful misconduct of Ohio State. The license agreements for AR-12 and AR-42 each expire on the later of (i) the expiration of the last valid claim contained in any licensed patent and (ii) 20 years after the effective date of the license. Ohio State will generally be able to terminate either license upon the Company’s breach of the terms of the license to the extent the Company fails to cure any such breach within 90 days after receiving notice of such breach or the Company files for bankruptcy. The Company may terminate either license upon 90 days prior written notice.

FAIR_VALUE_OF_FINANCIAL_INSTRU

FAIR VALUE OF FINANCIAL INSTRUMENTS	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
FAIR VALUE OF FINANCIAL INSTRUMENTS	'
	6. FAIR VALUE OF FINANCIAL INSTRUMENTS
	The Company defines fair value as the amount at which an asset (or liability) could be bought (or incurred) or sold (or settled) in a current transaction between willing parties, that is, other than in a forced or liquidation sale. The fair value estimates presented in the table below are based on information available to the Company as of June 30, 2014.
	The accounting standard regarding fair value measurements discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:
		•	Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
		•	Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
		•	Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions.
	The Company has determined the fair value of certain liabilities using the market approach. The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of June 30, 2014:
					Quoted Market
					Prices in Active		Significant Other		Significant Other
			Fair Value		Markets		Observable Inputs		Unobservable Inputs
			June 30, 2014		(Level 1)		(Level 2)		(Level 3)
	Liabilities:
	Warrant liability - 2010 Series B		$	224,528	$	-	$	-	$	224,528
	Warrant liability - 2012 Series A&B			10,338,102		-		-		10,338,102
	Warrant liability - 2012 placement agent			224,160		-		-		224,160
	Warrant liability - 2013 Series D&E			10,037,496		-		-		10,037,496
	Warrant liability - 2013 placement agent			57,115		-		-		57,115
	Total		$	20,881,401	$	-	$	-	$	20,881,401
	The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of December 31, 2013:
					Quoted Market
					Prices in Active		Significant Other		Significant Other
			Fair Value		Markets		Observable Inputs		Unobservable Inputs
			December 31, 2013		(Level 1)		(Level 2)		(Level 3)
	Liabilities:
	Warrant liability - 2010 Series B		$	362,452	$	-	$	-	$	362,452
	Warrant liability - 2012 Series A&B			16,703,983		-		-		16,703,983
	Warrant liability - 2012 placement agent			362,633		-		-		362,633
	Warrant liability - 2013 Series D&E			18,337,733		-		-		18,337,733
	Warrant liability - 2013 placement agent			98,080		-		-		98,080
	Total		$	35,864,881	$	-	$	-	$	35,864,881
	The following table provides a summary of changes in fair value of the Company’s liabilities, as well as the portion of losses included in income attributable to unrealized depreciation that relate to those liabilities held June 30, 2014:
	Fair Value Measurement Using Significant Unobservable Inputs (Level 3)
			Total						2013						2012				Debenture
			Warrant		2013		2013		Placement		2012		2012		Placement		2010		Conversion
			Liability		Series E		Series D		Agent		Series B		Series A		Agent		Series B		Feature
	Balance at January 1, 2013		$	21,420,276	$	-	$	-	$	-	$	5,744,784	$	6,685,740	$	542,530	$	898,722	$	7,548,500
	Purchase, sales and settlements:
	Warrants and other derivatives issued			15,681,151		5,057,354		10,552,240		71,557
	Settlement of derivatives			-5,403,000																-5,403,000
	Total gains or losses:
	Unrealized depreciation/(appreciation)			4,166,454		797,852		1,930,287		26,523		-2,928,108		7,201,567		-179,897		-536,270		-2,145,500
	Balance at January 1, 2014		$	35,864,881	$	5,855,206	$	12,482,527	$	98,080	$	2,816,676	$	13,887,307	$	362,633	$	362,452	$	-
	Purchase, sales and settlements:
	Warrants and other derivatives issued
	Settlement of derivatives
	Total gains or losses:
	Unrealized depreciation/(appreciation)			-14,983,480		-4,310,976		-3,989,261		-40,965		-2,073,816		-4,292,065		-138,473		-137,924
	Balance at June 30, 2014		$	20,881,401	$	1,544,230	$	8,493,266	$	57,115	$	742,860	$	9,595,242	$	224,160	$	224,528	$	-
	Value per Warrant		$	0.48	$	0.12	$	0.66	$	0.87	$	0.12	$	0.93	$	0.79	$	0.28

STOCKHOLDERS_EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Jun. 30, 2014
Stockholders Equity Note [Abstract]	'
STOCKHOLDERS' EQUITY	'
	7. STOCKHOLDERS’ EQUITY
	Common Stock
	The Company amended its Amended & Restated Certificate of Incorporation, effective as of October 29, 2013, to effect a combination of its common stock at a ratio of 1-for-8 (the “Reverse Split”). The Reverse Split was effective immediately prior to the entry into the 2013 Purchase Agreement (defined below). The Reverse Split was authorized by the stockholders of the Company on November 10, 2010.
	As a result of the Reverse Split, all references to common stock, stock options and warrants and other securities convertible into common stock, and per share amounts for all prior periods presented have been retroactively restated to reflect the 1-for-8 reverse stock split of common stock.
	On November 26, 2012, the Company entered into a Securities Purchase Agreement, or the 2012 Purchase Agreement, with a number of institutional and accredited investors pursuant to which the Company sold in a private placement an aggregate principal amount of $14,857,200 of three-year 8% Senior Convertible Debentures, or the Debentures, plus the 2012 Warrants (defined below). On October 29, 2013, the Company entered into a Conversion Agreement (the “Conversion Agreement”) with the holders (the “Holders”) of its Debentures. Pursuant to the Conversion Agreement, the Holders agreed to convert the entire outstanding principal amount of their Debentures, together with accrued and unpaid interest through October 29, 2013, into shares of the Company’s common stock at a conversion price of $2.40 per share for a total of approximately 6,530,154 shares, of which 345,606 shares were issued in satisfaction of accrued and unpaid interest. As a result of such conversion, all of the Company’s obligations under the Debentures were fully satisfied.
	The Company also entered into a Registration Rights Agreement on November 26, 2012 (the “2012 Registration Rights Agreement”), with the purchasers of the Debentures pursuant to which the Company agreed to register the resale of the common stock underlying the Debentures and the 2012 Warrants. Pursuant to the terms of an amendment to the 2012 Registration Rights Agreement entered into on March 25, 2013, the Company was permitted, in its sole discretion, to pay liquidated damages resulting from the Company’s failure to successfully cause the registration statement covering the resale of 100% of the securities covered by the 2012 Purchase Agreement to be declared effective by the SEC by March 26, 2013, in common stock. In accordance with the amended Registration Rights Agreement, the Company issued common stock as follows:
		i)	On March 27, 2013, the Company issued an aggregate of approximately 123,809 shares of common stock to the investors in lieu of an aggregate cash payment of $297,143, representing the first installment of liquidated damages under the Registration Rights Agreement, as amended.
		ii)	On April 29, 2013, the Company issued an aggregate of approximately 136,536 shares of common stock to the investors in lieu of an aggregate cash payment of $327,688, representing the second installment of liquidated damages under the Registration Rights Agreement, as amended.
		iii)	On May 27, 2013, the Company issued an aggregate of approximately 120,280 shares of common stock to the investors in lieu of an aggregate cash payment of $288,674, representing the third and final installment of liquidated damages under the Registration Rights Agreement, as amended.
	On October 29, 2013, the Company entered into a Securities Purchase Agreement (the “2013 Purchase Agreement”) with certain purchasers identified therein (the “Purchasers”) pursuant to which the Company sold and the Purchasers purchased, an aggregate of 12,868,585 units of the Company’s securities (the “Units”), with each Unit consisting of the following:
		(i)	either (a) one share of common stock (each a “Share,” and collectively, the “Shares”), or (b) a five-year common stock warrant to purchase one share of common stock (collectively, the “Series C Warrant Shares”) at an exercise price of $0.01 per share (collectively, the “Series C Warrants”);
		(ii)	a five-year warrant to purchase one share of common stock (collectively, the “Series D Warrant Shares”) at an exercise price of $4.00 per share (collectively, the “Series D Warrants”); and
		(iii)	a warrant, expiring on October 31, 2014, to purchase one share of common stock (collectively, the “Series E Warrant Shares,” and together with the Series C Warrant Shares and the Series D Warrant Shares, the “Warrant Shares”) at an exercise price of $2.40 per share (collectively, the “Series E Warrants,” and together with the Series C Warrants and the Series D Warrants, the “2013 Warrants”).
	The Company sold and issued 8,413,354 Units consisting of Shares, Series D Warrants and Series E Warrants at a purchase price of $2.40 per Unit, and 4,455,231 Units consisting of Series C Warrants, Series D Warrants and Series E Warrants at a purchase price of $2.39 per Unit, for total gross proceeds to the Company of $30.84 million, before deducting fees and other transaction related expenses of approximately $760,000. A closing of the sale of 12,826,752 Units was completed on October 29, 2013, and the sale of the remaining 41,833 Units was completed on October 30, 2013.
	The 2013 Purchase Agreement contains customary representations, warranties and covenants by each of the Company and the Purchasers. In addition, the 2013 Purchase Agreement provides that each Purchaser has a right, subject to certain exceptions described in the agreement, to participate in future issuances of equity and debt securities by the Company for a period of 18 months following the effective date of the Registration Statement (defined below).
	Contemporaneously with the entry into the 2013 Purchase Agreement, and as contemplated thereby, the Company entered into a Registration Rights Agreement with the Purchasers. Pursuant to the terms of the Registration Rights Agreement, the Company agreed to file, on or before December 30, 2013 (the “Filing Date”), a registration statement under the Securities Act covering the resale of the Shares and Warrant Shares (the “Registration Statement”), and to cause such Registration Statement to be declared effective by the Commission as soon as practicable thereafter, but not later than 120 days following the date of the Registration Rights Agreement (the “Effectiveness Date”). The Registration Statement was declared effective on January 27, 2014. The Company is required to maintain the effectiveness of the Registration Statement until all of the shares covered thereby are sold or may be sold pursuant to Rule 144 under the Securities Act without volume or manner of- sale restrictions and without the requirement that the Company be in compliance with the current public information requirements of Rule 144.
	As of June 30, 2014, the Company had 20,370,331 shares of common stock issued and outstanding and approximately 55,920,214 shares of common stock reserved for issuance upon the exercise of outstanding options and warrants.
	Warrants
	In accordance with the 2010 sale and issuance of Series A preferred stock, the Company issued two-and-one-half-year “Class A” warrants to purchase an aggregate of 152,740 shares of Series A Preferred Stock at an initial exercise price of $8.00 per share (the “2010 Class A Warrants”) and five-year Class B warrants to purchase an aggregate of 801,885 shares of Series A Preferred Stock at an initial exercise price of $9.20 per share (the “2010 Class B Warrants,” and together with the 2010 Class A Warrants, the “2010 Warrants”). Upon the automatic conversion of the Series A Preferred Stock in January 2011, the 2010 Warrants automatically converted to the right to purchase an equal number of shares of common stock. The terms of the warrants contain an anti-dilutive price adjustment provision, such that, in the event the Company issues common shares at a price below the current exercise price of the 2010 Warrants, the exercise price will be decreased pursuant to a customary “weighted-average” formula. In accordance with this provision and as a result of the issuances made pursuant to the 2012 Purchase Agreement and 2013 Purchase Agreement, the exercise price of the 2010 Class B warrants has been adjusted to $3.55 per share. Because of this anti-dilution provision and the inherent uncertainty as to the probability of future common share issuances, the Black-Scholes option pricing model the Company uses for valuing stock options could not be used. Management used a Monte Carlo simulation model and, in doing so, utilized a third-party valuation report to determine the warrant liability to be approximately $0.2 million and approximately $0.4 million at June 30, 2014 and December 31, 2013, respectively. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error. This valuation is revised on a quarterly basis until the warrants are exercised or they expire with the changes in fair value recorded in other income (expense) on the statement of operations. The 2010 Class A warrants, representing the right to purchase an aggregate of 152,740 shares of common stock, expired during the year ended December 31, 2013 unexercised.
	Pursuant to the 2012 Purchase Agreement, the Company issued five-year Series A warrants to purchase an aggregate of approximately 6,190,500 shares of common stock at an initial exercise price of $4.00 per share and 18-month Series B warrants to purchase an aggregate of approximately 6,190,500 shares of common stock at an initial exercise price of $2.40 per share. The terms of the 2012 Warrants contain a “full-ratchet” anti-dilutive price adjustment provision. In accordance with such full-ratchet anti-dilution provision, in the event that the Company sells or issues additional shares of common stock, including securities convertible or exchangeable for common stock (subject to customary exceptions), at a per share price less than the applicable 2012 Warrant exercise price, such warrant exercise price will be reduced to an amount equal to the issuance price of such subsequently issued shares; after such time as the Company has raised at least $12 million in additional equity financing, the 2012 Warrants are subject to further anti-dilution protection based on a weighted-average formula. Further, the anti-dilution provisions of the 2012 Warrants provide that, in addition to a reduction in the applicable exercise price, the number of shares purchasable thereunder is increased such that the aggregate exercise price of the warrants (exercise price per share multiplied by total number of shares underlying the warrants) remained unchanged. In accordance with the terms of this anti-dilution provision and as a result of the Company’s issuances under the 2013 Purchase Agreement, the exercise price of the Series A warrants was reduced to $2.40 per share and the aggregate number of shares underlying such warrants was increased to 10,317,464 shares. Because of this anti-dilution provision and the inherent uncertainty as to the probability of future common share issuances, the Black-Scholes option pricing model the Company uses for valuing stock options could not be used. Management used a Monte Carlo simulation model and, in doing so, utilized a third-party valuation report to determine the warrant liability to be approximately $10.3 million and $16.7 million at June 30, 2014 and December 31, 2013, respectively.
	In connection with the 2012 offering of the Debentures and 2012 Warrants, the Company engaged Maxim Group LLC, or Maxim Group, to serve as placement agent. In consideration for its services, the Company paid Maxim Group a placement fee of $1,035,000. In addition, the Company issued to Maxim Partners LLC, or Maxim Partners, an affiliate of Maxim Group, 7,500 shares of common stock and five-year warrants to purchase an additional 283,750 shares of common stock at an initial exercise price of $2.64 per share. The warrants issued to Maxim Partners are in substantially the same form as the Warrants issued to the investors, except that they do not include certain anti-dilution provisions contained in the Warrants. However, the placement warrants do contain a provision that could require the Company to repurchase the warrants from the holder under certain conditions. Management used a Monte Carlo simulation model and, in doing so, utilized a third-party valuation report to determine the warrant liability to be approximately $0.2 million and $0.4 million at June 30, 2014 and December 31, 2013, respectively.
	Under the terms of the 2013 Purchase Agreement, each Purchaser had the option to elect to receive a Series C Warrant in lieu of a Share in connection with each Unit it purchased. The Series C Warrants have a five-year term and are exercisable at an initial exercise price of $0.01 per share. The Series D Warrants have a five-year term and are exercisable at an initial exercise price of $4.00 per share, subject to adjustment for stock splits, combinations, recapitalization events and certain dilutive issuances (as described below). The Series E Warrants are exercisable until October 31, 2014 at an initial exercise price of $2.40 per share, subject to adjustment for stock splits, combinations, recapitalization events and certain dilutive issuances (as described below). The applicable exercise price of the Series D Warrants and Series E Warrants (but not the Series C Warrants) is subject to a weighted-average price adjustment in the event the Company makes future issuances of common stock or rights to acquire common stock (subject to certain exceptions) at a per share price less than the applicable warrant exercise price. Because of this anti-dilution provision and the inherent uncertainty as to the probability of future common share issuances, the Black-Scholes option pricing model the Company uses for valuing stock options could not be used. Management used a Monte Carlo simulation model and, in doing so, utilized a third-party valuation report to determine the warrant liability for the Series D and Series E Warrants to be approximately $10.0 million and $18.3 million at June 30, 2014 and December 31, 2013, respectively.
	The 2013 Warrants are required to be exercised for cash, provided that if during the term of the Warrants there is not an effective registration statement under the Securities Act covering the resale of the shares issuable upon exercise of the Warrants, then the Warrants may be exercised on a cashless (net exercise) basis.
	Below is a table that summarizes all outstanding warrants to purchase shares of the Company’s common stock as of June 30, 2014.
	Grant Date		Warrants		Exercise		Weighted Average		Expiration	Exercised		Warrants Outstanding
			Issued		Price		Exercise		Date
							Price
	9/3/10			801,885	$	3.55	$	3.55	9/3/15		-		801,885
	9/3/10			132,116	$	8.8	$	8.8	9/3/15		-		132,116
	11/26/12			5,293,738	$	2.4	$	2.4	10/31/14		-		5,293,738
	12/18/12			896,748	$	2.4	$	2.4	10/31/14		-		896,748
	11/26/12			8,822,887	$	2.4	$	2.4	11/26/17		-		8,822,887
	11/26/12			261,250	$	2.64	$	2.64	11/26/17		-		261,250
	12/18/12			1,494,577	$	2.4	$	2.4	12/18/17		-		1,494,577
	12/18/12			22,500	$	2.64	$	2.64	12/18/17		-		22,500
	10/29/13			4,455,231	$	0.01	$	0.01	10/29/18		-		4,455,231
	10/29/13			12,868,585	$	2.4	$	2.4	10/31/14		-		12,868,585
	10/29/13			12,868,585	$	4	$	4	10/29/18		-		12,868,585
	10/29/13			65,650	$	2.64	$	2.64	10/29/18		-		65,650
				47,983,752			$	2.65			-		47,983,752

STOCK_OPTION_PLAN

STOCK OPTION PLAN	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
STOCK OPTION PLAN	'
	8. STOCK OPTION PLAN
	The Company’s 2005 Stock Option Plan (the “Plan”) was originally adopted by the Board of Directors of Old Arno in August 2005, and was assumed by the Company on June 3, 2008 in connection with the Merger. After giving effect to the Merger, there were initially 373,831 shares of the Company’s common stock reserved for issuance under the Plan. On April 25, 2011, the Company’s Board of Directors (the “Board”) approved an amendment to the Plan to increase the number of shares of common stock issuable under the Plan to 875,000 shares. On January 14, 2013, the Company’s Board of Directors approved an amendment to the Plan to increase the number of shares of common stock issuable under the Plan to 945,276 shares. On October 7, 2013, the Company’s Board of Directors adopted an amendment to the Company’s 2005 Plan, as amended that increased the number of shares of common stock authorized for issuance thereunder from 945,276 to 11,155,295. Under the Plan, incentives may be granted to officers, employees, directors, consultants, and advisors. Incentives under the Plan may be granted in any one or a combination of the following forms: (a) incentive stock options and non-statutory stock options, (b) stock appreciation rights, (c) stock awards, (d) restricted stock and (e) performance shares.
	The Plan is administered by the Board, or a committee appointed by the Board, which determines recipients and types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. The term of stock options granted under the Plan cannot exceed 10 years. Options shall not have an exercise price less than the fair market value of the Company’s common stock on the grant date, and generally vest over a period of three to four years.
	As of June 30, 2014, there are 3,178,854 shares available for future grants and awards under the Plan, which covers stock options, warrants and restricted awards.
	The Company issued the following stock options during the three and six month periods ended June 30, 2014 and June 30, 2013, respectively.
			Three months ended June 30,						Six months ended June 30,
			2014			2013			2014			2013
	Options granted			-			6,250			2,186,957			182,938
	The Company estimated the fair value of each option award granted using the Black-Scholes option-pricing model. The following assumptions were used for the three and six months ended June 30, 2014 and June 30, 2013:
			Three months ended June 30,						Six months ended June 30,
			2014		2013				2014			2013
	Expected volatility		N/A			96%			92%				89% - 96%
	Expected term		N/A			5 years			6 years				4-6 years
	Dividend yield		N/A			0.00%			0.00%				0.00%
	Risk- free interest rate		N/A			0.77%			1.57% - 1.58%				0.77% - 0.89%
	Stock price		N/A			$2.40			$2.23 - $2.90				$2.40
	Forfeiture rate		N/A			0.00%			0.00%				0.00%
	A summary of the status of the options issued under the Plan at June 30, 2014, and information with respect to the changes in options outstanding is as follows:
						Options Outstanding
			Shares			Outstanding			Weighted-			Aggregate
			Available for			Stock Options			Average			Intrinsic
			Grant						Exercise Price			Value
	Balance at January 1, 2014			5,396,832			5,758,463		$	2.66		$	-
	Shares authorized for issuance			-			-			-			-
	Options granted under the Plan			-2,186,957			2,186,957		$	2.83			-
	Options exercised			-			-			-			-
	Options forfeited			8,959			-8,959		$	24			-
	Balance at June 30, 2014			3,218,834			7,936,461		$	2.68		$	-
	Exercisable at June 30, 2014						1,355,051		$	3.37		$	-
	The following table summarizes information about stock options outstanding at June 30, 2014:
				Outstanding									Exercisable
	Exercise Price			Shares			Weighted-			Weighted-			Shares			Weighted-
							Average			Average						Average
							Remaining			Exercise						Exercise Price
							Contractual			Price
							Life (Years)
	$	2.23			223,445			9.65		$	2.23			-		$	2.23
	$	2.4			5,594,152			9.08		$	2.4			1,154,067		$	2.4
	$	2.9			1,963,512			9.57		$	2.9			45,632		$	2.9
	$	8			117,969			3.57		$	8			117,969		$	8
	$	19.38			37,383			3.78		$	19.38			37,383		$	19.38
	Total				7,936,461			9.11		$	2.68			1,355,051		$	3.37
	Stock-based compensation costs under the Plan for the three and six month periods ended June 30, 2014 and 2013 and for the cumulative period from August 1, 2005 (inception) through June 30, 2014 are as follows:
															Period from
															August 1, 2005
			Three months ended June 30,						Six months ended June 30,						(inception) to
			2014			2013			2014			2013			June 30, 2014
	Research and development		$	300,259		$	106,416		$	547,586		$	324,682		$	3,106,937
	General and administrative			952,714			128,855			1,870,443			374,616			4,439,083
	Total		$	1,252,973		$	235,271		$	2,418,029		$	699,298		$	7,546,020
	The fair value of options vested under the Plan was approximately $955,740 and $156,999 for the three months ended June 30, 2014 and 2013, respectively, approximately $1,916,729 and $544,804 for the six months ended June 30, 2014 and 2013, respectively and approximately $6,569,872 for the period from August 1, 2005 (inception) through June 30, 2014.
	At June 30, 2014, total unrecognized estimated compensation cost related to stock options granted prior to that date was approximately $11,858,796 which is expected to be recognized over a weighted-average vesting period of 2.7 years. This unrecognized estimated employee compensation cost does not include any estimate for forfeitures of performance-based stock options.
	Common stock, stock options or other equity instruments issued to non-employees (including consultants and all members of the Company’s Scientific Advisory Board) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of stock options is determined using the Black-Scholes option-pricing model and is expensed as the underlying options vest. The fair value of any options issued to non-employees is recorded as expense over the applicable service periods.

RELATED_PARTIES

RELATED PARTIES	6 Months Ended
	Jun. 30, 2014
Related Party Transactions [Abstract]	'
RELATED PARTIES	'
	9. RELATED PARTIES
	On June 1, 2009, the Company entered into a services agreement with Two River Consulting, LLC (“TRC”) to provide various clinical development, operational, managerial, accounting and financial, and administrative services to the Company for a period of one year. David M. Tanen, a director and Secretary of the Company and at the time also its President, Arie S. Belldegrun, M.D., the Chairman of the Board of Directors, and Joshua A. Kazam, a director until September 2010, are each partners of TRC. The terms of the Services Agreement were reviewed and approved by a special committee of the Company’s Board of Directors consisting of independent directors. None of the members of the special committee has any interest in TRC or the services agreement. As compensation for the services contemplated by the services agreement, the Company paid TRC a monthly cash fee of $55,000. The services agreement with TRC expired on April 1, 2011 and from that point until December 31, 2013, TRC billed the Company for actual hours worked on a monthly basis. For the three and six month periods ended June 30, 2013, TRC billed the Company $67,974 and $144,126, respectively. For the period from inception to December 31, 2013, TRC billed the Company a total of $2,052,571. As of January 1, 2014, the Company no longer received services from TRC.
	On occasion, some of the Company’s expenses were paid by TRC. No interest is charged by TRC on any outstanding balance owed by the Company. For the period from August 1, 2005 (inception) through June 30, 2014 services and reimbursed expenses totaled $2,482,958. As of March 31, 2014, the Company had a payable to TRC of $3,814, which was paid in full during the second quarter of 2014. There is no outstanding payable to TRC as of June 30 2014.
	The financial condition and results of operations of the Company, as reported, are not necessarily indicative of results that would have been reported had the Company operated completely independently.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2014
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	10. SUBSEQUENT EVENTS
	On July 17, 2014, the Board of Directors of the Company appointed Alexander Zukiwski, M.D., as interim Chief Executive Officer, in addition to his current position as Chief Medical Officer. On the same date, the Board also appointed Lawrence Kenyon as Chief Operating Officer, in addition to his current position as Chief Financial Officer. Dr. Zukiwski replaced Glenn R. Mattes, whose employment with the Company terminated on July 18, 2014.
	On July 25, 2014, the Company and Mr. Mattes entered into a separation agreement, pursuant to which they mutually agreed that Mr. Mattes’ employment with the Company, as well as the Employment Agreement between the Company and Mr. Mattes dated April 25, 2011, terminated on July 18, 2014. Mr. Mattes also resigned as a director of the Company effective as of such date. In accordance with the terms of the separation agreement, the Company agreed to (i) continue to pay to Mr. Mattes his current annualized base salary for a period of 13 months following the separation date, which amounts to an aggregate of $426,508.33; (ii) extended the termination date of all vested stock options held by Mr. Mattes as of the separation date until July 18, 2017; and (iii) allow such stock options to be exercised on a cashless (net) exercise basis. Accordingly, as of the separation date, Mr. Mattes holds stock options to purchase 432,896 shares of the Company’s common stock, all of which are exercisable at $2.40 per share. The separation agreement also provided for a release by Mr. Mattes of all claims.

BASIS_OF_PRESENTATION_AND_SUMM1

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Research and Development	'
	Research and Development
	Research and development costs are charged to expense as incurred. Research and development includes employee costs, fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated office, insurance, depreciation, and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the trial and the invoices received from its external service providers. The Company adjusts its accruals when actual costs become known. Costs related to the acquisition of technology rights for which development work is still in process are charged to operations as incurred and considered a component of research and development expense.
Warrant Liability	'
	Warrant Liability
	The Company accounts for the warrants issued in connection with the 2013, 2012 and 2010 Purchase Agreements (see Note 7) in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classify the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. The fair value of warrants issued by the Company, in connection with private placements of securities, has been estimated using a Monte Carlo simulation model and, in doing so, the Company’s management utilized a third-party valuation report. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error.

BASIC_AND_DILUTED_INCOMELOSS_P1

BASIC AND DILUTED INCOME/(LOSS) PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share, Basic and Diluted [Abstract]	'
Schedule of Earnings Per Share, Basic and Diluted	'
	The following table is a reconciliation of the numerator and denominator used in the calculation of basic and diluted net income/(loss) per share.
		Three months ended June 30,				Six months ended June 30,
		2014		2013		2014		2013
	Numerator:
	Net income/(loss)	$	3,494,633	$	-11,304,830	$	3,048,192	$	-12,238,718
	Denominator:
	Weighted-average shares of common stock outstanding used in the calculation of basic net income/(loss) per share		20,370,331		4,814,822		20,370,331		4,684,384
	Effect of dilutive securities:
	Warrants to purchase common stock		4,432,191		-		4,434,632		-
	Weighted-average shares of common stock outstanding used in the calculation of diluted net income/(loss) per share		24,802,522		4,814,822		24,804,963		4,684,384

FAIR_VALUE_OF_FINANCIAL_INSTRU1

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Hierarchy for Liabilities Measured at Fair Value on Recurring Basis	'
	The Company has determined the fair value of certain liabilities using the market approach. The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of June 30, 2014:
				Quoted Market
				Prices in Active		Significant Other		Significant Other
		Fair Value		Markets		Observable Inputs		Unobservable Inputs
		June 30, 2014		(Level 1)		(Level 2)		(Level 3)
	Liabilities:
	Warrant liability - 2010 Series B	$	224,528	$	-	$	-	$	224,528
	Warrant liability - 2012 Series A&B		10,338,102		-		-		10,338,102
	Warrant liability - 2012 placement agent		224,160		-		-		224,160
	Warrant liability - 2013 Series D&E		10,037,496		-		-		10,037,496
	Warrant liability - 2013 placement agent		57,115		-		-		57,115
	Total	$	20,881,401	$	-	$	-	$	20,881,401
	The following table presents the Company’s fair value hierarchy for these assets measured at fair value on a recurring basis as of December 31, 2013:
				Quoted Market
				Prices in Active		Significant Other		Significant Other
		Fair Value		Markets		Observable Inputs		Unobservable Inputs
		December 31, 2013		(Level 1)		(Level 2)		(Level 3)
	Liabilities:
	Warrant liability - 2010 Series B	$	362,452	$	-	$	-	$	362,452
	Warrant liability - 2012 Series A&B		16,703,983		-		-		16,703,983
	Warrant liability - 2012 placement agent		362,633		-		-		362,633
	Warrant liability - 2013 Series D&E		18,337,733		-		-		18,337,733
	Warrant liability - 2013 placement agent		98,080		-		-		98,080
	Total	$	35,864,881	$	-	$	-	$	35,864,881
Summary of Changes in Fair Value of Liabilities	'
	The following table provides a summary of changes in fair value of the Company’s liabilities, as well as the portion of losses included in income attributable to unrealized depreciation that relate to those liabilities held June 30, 2014:
	Fair Value Measurement Using Significant Unobservable Inputs (Level 3)
		Total						2013						2012				Debenture
		Warrant		2013		2013		Placement		2012		2012		Placement		2010		Conversion
		Liability		Series E		Series D		Agent		Series B		Series A		Agent		Series B		Feature
	Balance at January 1, 2013	$	21,420,276	$	-	$	-	$	-	$	5,744,784	$	6,685,740	$	542,530	$	898,722	$	7,548,500
	Purchase, sales and settlements:
	Warrants and other derivatives issued		15,681,151		5,057,354		10,552,240		71,557
	Settlement of derivatives		-5,403,000																-5,403,000
	Total gains or losses:
	Unrealized depreciation/(appreciation)		4,166,454		797,852		1,930,287		26,523		-2,928,108		7,201,567		-179,897		-536,270		-2,145,500
	Balance at January 1, 2014	$	35,864,881	$	5,855,206	$	12,482,527	$	98,080	$	2,816,676	$	13,887,307	$	362,633	$	362,452	$	-
	Purchase, sales and settlements:
	Warrants and other derivatives issued
	Settlement of derivatives
	Total gains or losses:
	Unrealized depreciation/(appreciation)		-14,983,480		-4,310,976		-3,989,261		-40,965		-2,073,816		-4,292,065		-138,473		-137,924
	Balance at June 30, 2014	$	20,881,401	$	1,544,230	$	8,493,266	$	57,115	$	742,860	$	9,595,242	$	224,160	$	224,528	$	-
	Value per Warrant	$	0.48	$	0.12	$	0.66	$	0.87	$	0.12	$	0.93	$	0.79	$	0.28

STOCKHOLDERS_EQUITY_Tables

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended
	Jun. 30, 2014
Stockholders Equity Note [Abstract]	'
Summary of All Outstanding Warrants to Purchase Shares of Common Stock	'
	Below is a table that summarizes all outstanding warrants to purchase shares of the Company’s common stock as of June 30, 2014.
	Grant Date	Warrants		Exercise		Weighted Average		Expiration	Exercised		Warrants Outstanding
		Issued		Price		Exercise		Date
						Price
	9/3/10		801,885	$	3.55	$	3.55	9/3/15		-		801,885
	9/3/10		132,116	$	8.8	$	8.8	9/3/15		-		132,116
	11/26/12		5,293,738	$	2.4	$	2.4	10/31/14		-		5,293,738
	12/18/12		896,748	$	2.4	$	2.4	10/31/14		-		896,748
	11/26/12		8,822,887	$	2.4	$	2.4	11/26/17		-		8,822,887
	11/26/12		261,250	$	2.64	$	2.64	11/26/17		-		261,250
	12/18/12		1,494,577	$	2.4	$	2.4	12/18/17		-		1,494,577
	12/18/12		22,500	$	2.64	$	2.64	12/18/17		-		22,500
	10/29/13		4,455,231	$	0.01	$	0.01	10/29/18		-		4,455,231
	10/29/13		12,868,585	$	2.4	$	2.4	10/31/14		-		12,868,585
	10/29/13		12,868,585	$	4	$	4	10/29/18		-		12,868,585
	10/29/13		65,650	$	2.64	$	2.64	10/29/18		-		65,650
			47,983,752			$	2.65			-		47,983,752

STOCK_OPTION_PLAN_Tables

STOCK OPTION PLAN (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]	'
Schedule of Share-based Compensation, Activity	'
			Three months ended June 30,						Six months ended June 30,
			2014			2013			2014			2013
	Options granted			-			6,250			2,186,957			182,938
Assumptions Used in Estimating Fair Value of Each Option Award Granted Using Black-Scholes Option-Pricing Model	'
	The Company estimated the fair value of each option award granted using the Black-Scholes option-pricing model. The following assumptions were used for the three and six months ended June 30, 2014 and June 30, 2013:
			Three months ended June 30,						Six months ended June 30,
			2014		2013				2014			2013
	Expected volatility		N/A			96%			92%				89% - 96%
	Expected term		N/A			5 years			6 years				4-6 years
	Dividend yield		N/A			0.00%			0.00%				0.00%
	Risk- free interest rate		N/A			0.77%			1.57% - 1.58%				0.77% - 0.89%
	Stock price		N/A			$2.40			$2.23 - $2.90				$2.40
	Forfeiture rate		N/A			0.00%			0.00%				0.00%
Summary of Status of Options Issued And Changes in Options Outstanding	'
	A summary of the status of the options issued under the Plan at June 30, 2014, and information with respect to the changes in options outstanding is as follows:
						Options Outstanding
			Shares			Outstanding			Weighted-			Aggregate
			Available for			Stock Options			Average			Intrinsic
			Grant						Exercise Price			Value
	Balance at January 1, 2014			5,396,832			5,758,463		$	2.66		$	-
	Shares authorized for issuance			-			-			-			-
	Options granted under the Plan			-2,186,957			2,186,957		$	2.83			-
	Options exercised			-			-			-			-
	Options forfeited			8,959			-8,959		$	24			-
	Balance at June 30, 2014			3,218,834			7,936,461		$	2.68		$	-
	Exercisable at June 30, 2014						1,355,051		$	3.37		$	-
Summary of Stock Options Outstanding	'
	The following table summarizes information about stock options outstanding at June 30, 2014:
				Outstanding									Exercisable
	Exercise Price			Shares			Weighted-			Weighted-			Shares			Weighted-
							Average			Average						Average
							Remaining			Exercise						Exercise Price
							Contractual			Price
							Life (Years)
	$	2.23			223,445			9.65		$	2.23			-		$	2.23
	$	2.4			5,594,152			9.08		$	2.4			1,154,067		$	2.4
	$	2.9			1,963,512			9.57		$	2.9			45,632		$	2.9
	$	8			117,969			3.57		$	8			117,969		$	8
	$	19.38			37,383			3.78		$	19.38			37,383		$	19.38
	Total				7,936,461			9.11		$	2.68			1,355,051		$	3.37
Stock-Based Compensation Costs	'
	Stock-based compensation costs under the Plan for the three and six month periods ended June 30, 2014 and 2013 and for the cumulative period from August 1, 2005 (inception) through June 30, 2014 are as follows:
															Period from
															August 1, 2005
			Three months ended June 30,						Six months ended June 30,						(inception) to
			2014			2013			2014			2013			June 30, 2014
	Research and development		$	300,259		$	106,416		$	547,586		$	324,682		$	3,106,937
	General and administrative			952,714			128,855			1,870,443			374,616			4,439,083
	Total		$	1,252,973		$	235,271		$	2,418,029		$	699,298		$	7,546,020

Description_of_Business_Additi

Description of Business - Additional Information (Detail)	Jun. 30, 2014
Organization and Nature of Operations [Line Items]	'
Percentage of outstanding common stock collectively held by former stockholders of Old Arno	95.00%

Recovered_Sheet1

Basis of Presentation And Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Summary Of Significant Accounting Policies [Line Items]	'	'
Deficit accumulated during the development stage	$86,509,565	$89,557,757

Recovered_Sheet2

Liquidity and Capital Resources - Additional Information (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2013	Dec. 31, 2012	Jul. 31, 2005
Working Capital Detail [Line Items]	'	'	'	'	'
Cash and cash equivalents	$15,844,600	$26,774,203	$4,554,390	$10,943,437	$0

Schedule_of_Calculation_of_Num

Schedule of Calculation of Numerator and Denominator in Earnings Per Share (Detail) (USD $)	3 Months Ended		6 Months Ended		12 Months Ended			65 Months Ended	107 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Jun. 30, 2014
Numerator:	'	'	'	'	'	'	'	'	'
Net income/(loss)	$3,494,633	($11,304,830)	$3,048,192	($12,238,718)	($39,656,975)	($14,387,782)	($7,909,113)	($27,603,887)	($86,509,565)
Denominator:	'	'	'	'	'	'	'	'	'
Weighted-average shares of common stock outstanding used in the calculation of basic net income/(loss) per share	20,370,331	4,814,822	20,370,331	4,684,384	'	'	'	'	'
Effect of dilutive securities:	'	'	'	'	'	'	'	'	'
Warrants to purchase common stock	4,432,191	0	4,434,632	0	'	'	'	'	'
Weighted-average shares of common stock outstanding used in the calculation of diluted net income/(loss) per share	24,802,522	4,814,822	24,804,963	4,684,384	'	'	'	'	'

Recovered_Sheet3

Basic And Diluted Income/(Loss) Per Share - Additional Information (Detail)	3 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Antidilutive securities excluded from computation of earnings per share, amount	51,464,983	7,291,312

Recovered_Sheet4

Intangible Assets and Intellectual Property - Additional Information (Detail) (USD $)	0 Months Ended	6 Months Ended	1 Months Ended	0 Months Ended	1 Months Ended	12 Months Ended
	Feb. 13, 2012	Jun. 30, 2014	Oct. 31, 2013	Feb. 13, 2012	Jan. 31, 2014	Dec. 31, 2008	Dec. 31, 2008	Dec. 31, 2008
			Invivis Pharmaceuticals, Inc	Onapristone License Agreement	Onapristone License Agreement	AR-12 and AR-42 License Agreements	AR-12 License Agreement	AR-42 License Agreement
				Invivis Pharmaceuticals, Inc	Invivis Pharmaceuticals, Inc	Ohio State University Research Foundation	Ohio State University Research Foundation	Ohio State University Research Foundation
					Next Milestone Payment
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'	'	'
Cash paid under license agreement	'	'	$150,000	$500,000	$100,000	$450,000	'	'
Aggregate potential milestone payments	'	'	'	15,100,000	'	'	6,100,000	5,100,000
License agreement termination date	'	'	'	13-Feb-32	'	'	'	'
Written notice period for termination of license agreement if breach is not cured	'	'	'	'90 days	'	'90 days	'	'
Prior written notice period for termination of license agreement by the company for any reason	'	'	'	'90 days	'	'90 days	'	'
Potential milestone payments, due after market approval	'	'	'	'	'	'	5,000,000	4,000,000
License agreement expiration date	'	'	'	'	'	'20 years	'	'
Services agreement expire date	30-Apr-14	'	'	'	'	'	'	'
Services agreement monthly payment	$70,833	$50,000	'	'	'	'	'	'

Fair_Value_Hierarchy_for_Liabi

Fair Value Hierarchy for Liabilities Measured at Fair Value on Recurring Basis (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
Liabilities	'	'
Derivative Liabilities Noncurrent	$20,881,401	$35,864,881
Fair Value, Measurements, Recurring | Warrant liability - 2010 Series B	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	224,528	362,452
Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A&B	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	10,338,102	16,703,983
Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	224,160	362,633
Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D&E	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	10,037,496	18,337,733
Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	57,115	98,080
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2010 Series B	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A&B	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D&E	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2010 Series B	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A&B	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D&E	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	0	0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	20,881,401	35,864,881
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2010 Series B	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	224,528	362,452
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A&B	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	10,338,102	16,703,983
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	224,160	362,633
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D&E	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	10,037,496	18,337,733
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent	'	'
Liabilities	'	'
Derivative Liabilities Noncurrent	$57,115	$98,080

Summary_of_Changes_in_Fair_Val

Summary of Changes in Fair Value of Liabilities (Detail) (USD $)	6 Months Ended	12 Months Ended
	Jun. 30, 2014	Dec. 31, 2013
Warrant	'	'
Warrant Liability	'	'
Balance	$35,864,881	$21,420,276
Purchases, sales and settlements:	'	'
Warrants and other derivatives issued	'	15,681,151
Settlement of derivatives	'	-5,403,000
Total gains or losses:	'	'
Unrealized depreciation (appreciation)	-14,983,480	4,166,454
Balance	20,881,401	35,864,881
Value per Warrant	$0.48	'
2010 Series B	'	'
Warrant Liability	'	'
Balance	362,452	898,722
Total gains or losses:	'	'
Unrealized depreciation (appreciation)	-137,924	-536,270
Balance	224,528	362,452
Value per Warrant	$0.28	'
Debenture Conversion Feature	'	'
Warrant Liability	'	'
Balance	'	7,548,500
Purchases, sales and settlements:	'	'
Settlement of derivatives	'	-5,403,000
Total gains or losses:	'	'
Unrealized depreciation (appreciation)	'	-2,145,500
Balance	0	0
2013 Series E	'	'
Warrant Liability	'	'
Balance	5,855,206	0
Purchases, sales and settlements:	'	'
Warrants and other derivatives issued	'	5,057,354
Total gains or losses:	'	'
Unrealized depreciation (appreciation)	-4,310,976	797,852
Balance	1,544,230	5,855,206
Value per Warrant	$0.12	'
2013 Series D	'	'
Warrant Liability	'	'
Balance	12,482,527	0
Purchases, sales and settlements:	'	'
Warrants and other derivatives issued	'	10,552,240
Total gains or losses:	'	'
Unrealized depreciation (appreciation)	-3,989,261	1,930,287
Balance	8,493,266	12,482,527
Value per Warrant	$0.66	'
2012 Series A	'	'
Warrant Liability	'	'
Balance	13,887,307	6,685,740
Total gains or losses:	'	'
Unrealized depreciation (appreciation)	-4,292,065	7,201,567
Balance	9,595,242	13,887,307
Value per Warrant	$0.93	'
2012 Series B	'	'
Warrant Liability	'	'
Balance	2,816,676	5,744,784
Total gains or losses:	'	'
Unrealized depreciation (appreciation)	-2,073,816	-2,928,108
Balance	742,860	2,816,676
Value per Warrant	$0.12	'
2012 Placement Agent	'	'
Warrant Liability	'	'
Balance	362,633	542,530
Total gains or losses:	'	'
Unrealized depreciation (appreciation)	-138,473	-179,897
Balance	224,160	362,633
Value per Warrant	$0.79	'
2013 Placement Agent	'	'
Warrant Liability	'	'
Balance	98,080	0
Purchases, sales and settlements:	'	'
Warrants and other derivatives issued	'	71,557
Total gains or losses:	'	'
Unrealized depreciation (appreciation)	-40,965	26,523
Balance	$57,115	$98,080
Value per Warrant	$0.87	'

Stockholders_Equity_Additional

Stockholders' Equity - Additional Information (Detail) (USD $)

1 Months Ended

6 Months Ended

12 Months Ended

107 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

12 Months Ended

12 Months Ended

3 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

6 Months Ended

Oct. 29, 2013

Oct. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Jun. 30, 2014

Dec. 31, 2012

Nov. 26, 2012

Oct. 29, 2013

Oct. 29, 2013

27-May-13

Oct. 29, 2013

Oct. 29, 2013

Dec. 31, 2012

Jun. 30, 2014

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2010

Dec. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Oct. 31, 2014

Oct. 31, 2014

Mar. 27, 2013

Apr. 29, 2013

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Jun. 30, 2014

Jun. 30, 2014

Dec. 31, 2013

Purchase Agreement and 2013 Purchase Agreement

Securities Purchase Agreement

Securities Purchase Agreement

Conversion Agreement

Third And Final Installments

Common Stock

Common Stock

Maxim Group Llc

Maxim Group Llc

Maxim Group Llc

Class A Warrants

Class A Warrants

Class B Warrants

Class B Warrants

Series A Warrant

Series A Warrant

Series B Warrant

Series C Warrant

Series D Warrant

Series D Warrant

Series E Warrant

Series E Warrant

First Installment

Second Installment

Securities Purchase and Registration Rights Agreement

Securities Purchase and Registration Rights Agreement

Series D Warrants and Series E Warrants

Series D Warrants and Series E Warrants

Series C Warrants, Series D Warrants and Series E Warrants

Series A and B Warrants

Series A and B Warrants

Private Placement

Private Placement

Conversion Agreement

Series A Preferred Stock

Series A Preferred Stock

Purchase Agreement and 2013 Purchase Agreement

Subsequent Event

Series C Warrant

Series C Warrant

Stockholders Equity Note [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of common shares in lieu of liquidated damages (in shares)

'

'

'

'

'

'

'

'

'

'

'

120,280

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

123,809

136,536

'

'

'

'

'

'

'

Issuance of common shares in lieu of liquidated damages (in dollars)

'

'

'

'

$913,510

'

'

'

'

'

'

$288,674

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$297,143

$327,688

'

'

'

'

'

'

'

Common stock, shares issued

'

'

20,370,331

'

20,370,331

'

20,370,331

'

'

'

'

'

'

'

7,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock, Warrants or Units Issued During Period

'

'

47,983,752

'

'

'

47,983,752

6,190,500

'

'

'

'

'

'

283,750

'

'

152,740

152,740

'

801,885

10,317,464

'

6,190,500

'

'

'

'

'

'

'

'

'

8,413,354

'

4,455,231

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$2.64

'

'

'

$8

'

$9.20

$2.40

$4

$2.40

$4

'

$4

$2.40

$2.40

'

'

$0.01

$0.01

$2.40

'

$2.39

'

'

Warrant Term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'5 years

'

'18 months

'

'

'

'5 years

'5 years

'

'

'

'

'5 years

'

'

'

'

'

'

Derivative liabilities

'

'

20,881,401

'

35,864,881

'

20,881,401

'

'

'

'

'

'

'

'

200,000

400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,000,000

18,300,000

'

10,300,000

16,700,000

Placement Fee Paid

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,035,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders equity reverse stock split

'1-for-8 (the Reverse Split).

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Proceeds from the issuance of stock, warrants, or units

'

'

0

0

'

12,000,000

10,648,002

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30,840,000

'

'

Expense Related to Distribution or Servicing and Underwriting Fees

'

'

760,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock Issued During Period, Shares, Conversion of Units

12,826,752

41,833

'

'

'

'

'

'

'

'

6,530,154

'

12,868,585

345,606

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Annual Principal Payment

'

'

'

'

'

'

'

'

$14,857,200

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

'

'

'

'

8.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price

'

'

'

'

'

'

'

'

'

$2.40

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Term

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares Reserved for Future Issuance

'

'

55,920,214

'

'

'

55,920,214

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Summary_of_All_Outstanding_War

Summary of All Outstanding Warrants to Purchase Shares of Common Stock (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Class of Warrant or Right [Line Items]	'
Warrants Issued	47,983,752
Weighted- Average Exercise Price	2.65
Exercised	0
Warrants Outstanding	47,983,752
Warrant 1	'
Class of Warrant or Right [Line Items]	'
Grant Date	3-Sep-10
Warrants Issued	801,885
Exercise Price	$3.55
Weighted- Average Exercise Price	3.55
Expiration Date	3-Sep-15
Exercised	0
Warrants Outstanding	801,885
Warrant 2	'
Class of Warrant or Right [Line Items]	'
Grant Date	3-Sep-10
Warrants Issued	132,116
Exercise Price	$8.80
Weighted- Average Exercise Price	8.8
Expiration Date	3-Sep-15
Exercised	0
Warrants Outstanding	132,116
Warrant 3	'
Class of Warrant or Right [Line Items]	'
Grant Date	26-Nov-12
Warrants Issued	5,293,738
Exercise Price	$2.40
Weighted- Average Exercise Price	2.4
Expiration Date	31-Oct-14
Exercised	0
Warrants Outstanding	5,293,738
Warrant 4	'
Class of Warrant or Right [Line Items]	'
Grant Date	18-Dec-12
Warrants Issued	896,748
Exercise Price	$2.40
Weighted- Average Exercise Price	2.4
Expiration Date	31-Oct-14
Exercised	0
Warrants Outstanding	896,748
Warrant 5	'
Class of Warrant or Right [Line Items]	'
Grant Date	26-Nov-12
Warrants Issued	8,822,887
Exercise Price	$2.40
Weighted- Average Exercise Price	2.4
Expiration Date	26-Nov-17
Exercised	0
Warrants Outstanding	8,822,887
Warrant 6	'
Class of Warrant or Right [Line Items]	'
Grant Date	26-Nov-12
Warrants Issued	261,250
Exercise Price	$2.64
Weighted- Average Exercise Price	2.64
Expiration Date	26-Nov-17
Exercised	0
Warrants Outstanding	261,250
Warrant 7	'
Class of Warrant or Right [Line Items]	'
Grant Date	18-Dec-12
Warrants Issued	1,494,577
Exercise Price	$2.40
Weighted- Average Exercise Price	2.4
Expiration Date	18-Dec-17
Exercised	0
Warrants Outstanding	1,494,577
Warrant 8	'
Class of Warrant or Right [Line Items]	'
Grant Date	18-Dec-12
Warrants Issued	22,500
Exercise Price	$2.64
Weighted- Average Exercise Price	2.64
Expiration Date	18-Dec-17
Exercised	0
Warrants Outstanding	22,500
Warrant 9	'
Class of Warrant or Right [Line Items]	'
Grant Date	29-Oct-13
Warrants Issued	4,455,231
Exercise Price	$0.01
Weighted- Average Exercise Price	0.01
Expiration Date	29-Oct-18
Exercised	0
Warrants Outstanding	4,455,231
Warrant 10	'
Class of Warrant or Right [Line Items]	'
Grant Date	29-Oct-13
Warrants Issued	12,868,585
Exercise Price	$2.40
Weighted- Average Exercise Price	2.4
Expiration Date	31-Oct-14
Exercised	0
Warrants Outstanding	12,868,585
Warrant 11	'
Class of Warrant or Right [Line Items]	'
Grant Date	29-Oct-13
Warrants Issued	12,868,585
Exercise Price	$4
Weighted- Average Exercise Price	4
Expiration Date	29-Oct-18
Exercised	0
Warrants Outstanding	12,868,585
Warrant 12	'
Class of Warrant or Right [Line Items]	'
Grant Date	29-Oct-13
Warrants Issued	65,650
Exercise Price	$2.64
Weighted- Average Exercise Price	2.64
Expiration Date	29-Oct-18
Exercised	0
Warrants Outstanding	65,650

Stock_Option_Plan_Additional_I

Stock Option Plan - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

107 Months Ended

6 Months Ended

6 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jun. 30, 2014

Jan. 14, 2013

Apr. 25, 2011

Jun. 03, 2008

Oct. 07, 2013

Oct. 07, 2013

Employee Stock Option [Member]

Stock Options, Warrants Restricted Awards

Maximum

Minimum

2005 Plan

2005 Plan

2005 Plan

2005 Plan

2005 Plan

Maximum

Minimum

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares of common stock reserved for issuance under 2005 Plan

'

'

'

'

'

'

'

'

'

945,276

875,000

373,831

11,155,295

945,276

Term of stock options granted under 2005 Plan (in years)

'

'

'9 years 1 month 10 days

'

'

'10 years

'

'

'

'

'

'

'

'

Stock option vesting period

'

'

'

'

'

'

'

'4 years

'3 years

'

'

'

'

'

Fair value of options vested under 2005 Plan

$955,740

$156,999

$1,916,729

$544,804

$6,569,872

'

'

'

'

'

'

'

'

'

Total unrecognized estimated compensation cost related to stock options

$11,858,796

'

$11,858,796

'

$11,858,796

'

'

'

'

'

'

'

'

'

Total unrecognized estimated compensation cost related to stock options, recognition period

'

'

'2 years 8 months 12 days

'

'

'

'

'

'

'

'

'

'

'

Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant

'

'

'

'

'

'

3,178,854

'

'

'

'

'

'

'

Options_Granted_Detail

Options Granted (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]	'	'	'	'
Options granted	0	6,250	2,186,957	182,938

Assumptions_Used_in_Estimating

Assumptions Used in Estimating Fair Value of Each Option Award Granted Using Black-Scholes Option-Pricing Model (Detail) (USD $)	3 Months Ended	6 Months Ended
	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected Volatility	96.00%	92.00%	'
Expected Term	'5 years	'6 years	'
Dividend yield	0.00%	0.00%	0.00%
Risk-free interest rate	0.77%	'	'
Stock price	$2.40	'	$2.40
Forfeiture rate	0.00%	0.00%	0.00%
Minimum	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected Volatility	'	'	89.00%
Expected Term	'	'	'4 years
Risk-free interest rate	'	1.57%	0.77%
Stock price	'	2.23	'
Maximum	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'
Expected Volatility	'	'	96.00%
Expected Term	'	'	'6 years
Risk-free interest rate	'	1.58%	0.89%
Stock price	'	2.9	'

Summary_of_Status_of_Options_I

Summary of Status of Options Issued and Changes in Options Outstanding (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Outstanding Stock Options	'
Balance at June 30, 2014	7,936,461
Exercisable at June 30, 2014	1,355,051
Options Outstanding Weighted-Average Exercise Price	'
Balance at June 30, 2014	$2.68
Exercisable at June 30, 2014	$3.37
Stock Option Plan	'
Shares Available for Grant	'
Balance at January 1, 2014	5,396,832
Shares authorized for issuance	0
Options granted under the Plan	-2,186,957
Options exercised	0
Options forfeited	8,959
Balance at June 30, 2014	3,218,834
Outstanding Stock Options	'
Balance at January 1, 2014	5,758,463
Shares authorized for issuance	0
Options granted under the Plan	2,186,957
Options exercised	0
Options forfeited	-8,959
Balance at June 30, 2014	7,936,461
Exercisable at June 30, 2014	1,355,051
Options Outstanding Weighted-Average Exercise Price	'
Balance at January 1, 2014	$2.66
Shares authorized for issuance	$0
Options granted under the Plan	$2.83
Options exercised	$0
Options forfeited	$24
Balance at June 30, 2014	$2.68
Exercisable at June 30, 2014	$3.37
Options Outstanding Aggregate Intrinsic Value	'
Balance at January 1, 2014	$0
Shares authorized for issuance	0
Options granted under the Plan	0
Options exercised	0
Options forfeited	0
Balance at June 30, 2014	0
Exercisable at June 30, 2014	$0

Summary_of_Information_about_S

Summary of Information about Stock Options Outstanding (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Shares	7,936,461
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	'9 years 1 month 10 days
Options Outstanding, Weighted-Average Exercise Price	$2.68
Options Exercisable, Total Shares	1,355,051
Options Exercisable, Weighted- Average Exercise Price	$3.37
Exercise Price 1	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price	$2.23
Options Outstanding, Shares	223,445
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	'9 years 7 months 24 days
Options Outstanding, Weighted-Average Exercise Price	$2.23
Options Exercisable, Total Shares	0
Options Exercisable, Weighted- Average Exercise Price	$2.23
Exercise Price 2	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price	$2.40
Options Outstanding, Shares	5,594,152
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	'9 years 29 days
Options Outstanding, Weighted-Average Exercise Price	$2.40
Options Exercisable, Total Shares	1,154,067
Options Exercisable, Weighted- Average Exercise Price	$2.40
Exercise Price 3	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price	$2.90
Options Outstanding, Shares	1,963,512
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	'9 years 6 months 25 days
Options Outstanding, Weighted-Average Exercise Price	$2.90
Options Exercisable, Total Shares	45,632
Options Exercisable, Weighted- Average Exercise Price	$2.90
Exercise Price 4	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price	$8
Options Outstanding, Shares	117,969
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	'3 years 6 months 25 days
Options Outstanding, Weighted-Average Exercise Price	$8
Options Exercisable, Total Shares	117,969
Options Exercisable, Weighted- Average Exercise Price	$8
Exercise Price 5	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Options Outstanding, Exercise Price	$19.38
Options Outstanding, Shares	37,383
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	'3 years 9 months 11 days
Options Outstanding, Weighted-Average Exercise Price	$19.38
Options Exercisable, Total Shares	37,383
Options Exercisable, Weighted- Average Exercise Price	$19.38

StockBased_Compensation_Costs_

Stock-Based Compensation Costs (Detail) (USD $)	3 Months Ended		6 Months Ended		107 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'	'
Stock-based compensation costs	$1,252,973	$235,271	$2,418,029	$699,298	$7,546,020
Research and development	'	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'	'
Stock-based compensation costs	300,259	106,416	547,586	324,682	3,106,937
General and administrative	'	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'	'
Stock-based compensation costs	$952,714	$128,855	$1,870,443	$374,616	$4,439,083

Related_Parties_Additional_Inf

Related Parties - Additional Information (Detail) (USD $)	107 Months Ended		1 Months Ended	3 Months Ended	6 Months Ended	101 Months Ended
	Jun. 30, 2014	Dec. 31, 2013	Jun. 01, 2009	Jun. 30, 2013	Jun. 30, 2013	Dec. 31, 2013	Jun. 30, 2014
			Two River Consulting Llc	Two River Consulting Llc	Two River Consulting Llc	Two River Consulting Llc	Two River Consulting Llc
Related Party Transaction [Line Items]	'	'	'	'	'	'	'
Amount payable to TRC	$0	$26,039	'	'	'	'	$3,814
Related party transactions total billed amount for services rendered	'	'	'	67,974	144,126	'	'
Total cash services and reimbursed expenses	2,482,958	'	'	'	'	'	'
Related Party Transactions Billed Amount For Services Rendered Per Month	'	'	'	'	'	2,052,571	'
Consulting monthly cash fee paid	'	'	$55,000	'	'	'	'

SUBSEQUENT_EVENTS_Additional_I

SUBSEQUENT EVENTS - Additional Information (Detail) (USD $)	0 Months Ended	6 Months Ended
	Jul. 25, 2014	Jun. 30, 2014
Subsequent Event [Line Items]	'	'
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	'	1,355,051
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price	'	3.37
Subsequent Event [Member] | Mr. Mattes [Member]	'	'
Subsequent Event [Line Items]	'	'
Annualized Base Salary	$426,508.33	'
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number	432,896	'
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price	$2.40	'
Description on Terms of Separation Agreement	'	'(i) continue to pay to Mr. Mattes his current annualized base salary for a period of 13 months following the separation date, which amounts to an aggregate of $426,508.33; (ii) extended the termination date of all vested stock options held by Mr. Mattes as of the separation date until July 18, 2017; and (iii) allow such stock options to be exercised on a cashless (net) exercise basis. Accordingly, as of the separation date, Mr. Mattes holds stock options to purchase 432,896 shares of the Companys common stock, all of which are exercisable at $2.40 per share. The separation agreement also provided for a release by Mr. Mattes of all claims.